An Open Label, Multicenter Phase I Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies.
Phase of Trial: Phase I
Latest Information Update: 26 Jan 2013
At a glance
- Drugs Voruciclib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 Nov 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 06 Aug 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 22 May 2012 Status changed from active, no longer recruiting to completed according to a Piramal Healthcare media release.